Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity

• Published in: Diabetes & metabolism journal Vol. 39; no. 5; pp. 363 - 372
• Main Authors: Okada-Iwabu, Miki, Iwabu, Masato, Ueki, Kohjiro, Yamauchi, Toshimasa, Kadowaki, Takashi
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Diabetes Association 01.10.2015; 대한당뇨병학회
• Subjects: Adiponectin; AdipoR; Agonist; Crystal structure; Diabetes mellitus; Obesity; Review; 내과학; AdipoR; Obesity; Agonist; Diabetes mellitus; Adiponectin; Crystal structure
• ISSN: 2233-6079; 2233-6087
• DOI: 10.4093/dmj.2015.39.5.363

Obesity associated with unhealthy diet and lack of exercise is shown to contribute to the onset and/or aggravation of the metabolic syndrome and diabetes, thus placing affected individuals at increased risk of cardiovascular disease and cancer. Plasma adiponectin levels are decreased in obesity, which causes insulin resistance and diabetes. Therefore, we identified adiponectin receptors (AdipoRs) as the therapeutic target. It was suggested that, similarly to caloric restriction and exercise, activation of the AdipoRs may have the potential not only to improve lifestyle-related diseases but to contribute to prolonged the shortened lifespan on a high caloric unhealthy diet. To this end, we have identified "AdipoRon" as an adiponectin receptor agonist. Indeed, AdipoRon ameliorated diabetes associated with obesity as well as to increase exercise endurance, thus prolonging shortened lifespan of obese mice fed on a high fat diet. Additionally, we have recently determined the crystal structures of the human AdipoRs. The seven-transmembrane helices of AdipoRs are structurally distinct from those of G-protein coupled receptors. It is expected that these findings will contribute not only to the elucidation of the AdipoR-related signal transduction but to the development and optimization of AdipoR-targeted therapeutics for obesity-related diseases such as diabetes.